RxDoctor Payments Data

Barbara Williams, APRN

Family · Louisville, KYNPI 1316351208

Payments from drug & device makers

$838in general payments, 2019–2025

Across 27 payments — averaging $31.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$127
  • Bayer$124
  • Novo Nordisk$112
  • AbbVie$110
  • Lilly USA, LLC$107
  • Alkermes, Inc.$99
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$838 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,599
Medicare patients
128
Services billed
316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$67,603
EliquisApixaban37$43,537
JanuviaSitagliptin Phosphate30$41,000
KerendiaFinerenone35$31,743
OzempicSemaglutide30$27,617
MounjaroTirzepatide22$27,214
LinzessLinaclotide29$26,531
FarxigaDapagliflozin Propanediol20$18,490
Breo ElliptaFluticasone/Vilanterol23$16,386
XareltoRivaroxaban15$14,327
SymbicortBudesonide/Formoterol Fumarate36$10,031
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$9,031
VascepaIcosapent Ethyl13$7,604
Ventolin HfaAlbuterol Sulfate107$7,336
Spiriva HandihalerTiotropium Bromide11$6,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$43,53737 claims
BayerKerendia$124$31,74335 claims
Novo NordiskOzempic$112$27,61730 claims
Lilly USA, LLCMounjaro$107$27,21422 claims
AbbVieLinzess$110$26,53129 claims
Johnson & JohnsonXarelto$23$14,32715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →